Birznieks Gunther
SVP, Business Development
Birznieks Gunther has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Mar 4, 2026.
On the most recent filing, Birznieks Gunther is listed as SVP, Business Development at Vanda Pharmaceuticals Inc. Inside the rolling window, Birznieks Gunther reported no open-market purchases and 1 open-market sale totaling $351K in VNDA.
Companies traded
Other insiders at VNDA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$351K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Birznieks Gunther made?
Birznieks Gunther has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Birznieks Gunther trade?
Birznieks Gunther has filed SEC Form 4 disclosures for 1 company, including VNDA.
When was Birznieks Gunther's most recent SEC Form 4 filing?
Birznieks Gunther's most recent SEC Form 4 filing on Tracefour is dated Mar 4, 2026.
What is Birznieks Gunther's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Birznieks Gunther is listed as SVP, Business Development.
What is Birznieks Gunther's total buy and sell value in the current window?
Inside the rolling retention window, Birznieks Gunther bought $0 and sold $351K based on SEC Form 4 filings.
What was Birznieks Gunther's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 42,431 VNDA shares on 2026-03-02, worth $351K, per SEC Form 4 filings.